Abridge Stock

www.abridge.com/Healthcare / Healthcare softwareFounded: 2018

Abridge, founded in 2018, is a healthcare technology startup bringing generative AI to the medical field. The platform integrates with electronic health records (EHRs) to help healthcare providers minimize time spent on administrative tasks, enabling a focus on patient care. By summarizing medical notes and conversations, Abridge targets healthcare providers seeking to streamline documentation. The company is headquartered in Pittsburgh, Pennsylvania.

Register To Buy and Sell Shares

For more details on financing and valuation for Abridge, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Abridge’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Abridge.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Abridge investors also invested in these private companies

Team

Management Team

Shivdev Rao MD
Co-Founder & Chief Executive Officer
Julia Chapin
Chief Operating Officer
Sandeep Konam
Co-Founder & Chief Technology Officer
Zachary Lipton Ph.D
Chief Technology Officer, Chief Science Officer & Scientific Advisor
Tina Shah
Chief Clinical Officer
Brian Wilson
Chief Commercial Officer
Lindsey Spellman
Head of Marketing

Board Members

Andrew Weissman JD
Union Square Ventures

Frequently Asked Questions About Abridge’s Stock

plusminus
Can you buy Abridge’s stock?
Abridge is not publicly traded on NYSE or NASDAQ in the U.S. To buy Abridge’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Abridge’s stock?
Yes, you can sell stock of a private company like Abridge. Forge can help you sell your Abridge stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Abridge’s stock price?
Abridge is a privately held company and therefore does not have a public stock price. However, you may access Abridge’s private market stock price with Forge Data.
plusminus
What is Abridge’s stock ticker symbol?
Abridge does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Abridge raises $30M to Accelerate Adoption of its Proven Generative AI Solution across U.S. Healthcare Systems
Abridge, the leader in generative AI for clinical documentation, announced a Series B raise of $30 million, led by Spark Capital. The round also included existing investor Bessemer Venture Partners, as well as several leading healthcare innovators including CVS Health Ventures, Kaiser Permanente Ventures, Lifepoint Health, Mayo Clinic, SCAN Group, UC Investments (University of California), and the American College of Cardiology.
CVS, Mayo Clinic, Spark Capital back Abridge's $30M round to scale up generative AI-powered notetaking for doctors
Abridge launched in 2018 and uses AI to increase the speed and accuracy of medical note-taking, leveraging a proprietary dataset derived from more than 1.5 million medical encounters. Around 5,000 doctors currently use the company's software, which automatically converts a patient-clinician conversation into a structured clinical note draft in real-time. The company banked $30 million in a series B raise to support large-scale health system rollouts of its technology and accelerate product advances that will create additional value for patients, clinicians and health systems, the company said.
Updated on: Feb 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.